BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-1314. [PMID: 12818275 DOI: 10.1111/j.1572-0241.2003.07458.x] [Cited by in Crossref: 228] [Cited by in F6Publishing: 226] [Article Influence: 12.7] [Reference Citation Analysis]
Number Citing Articles
1 Hanevik K, Hausken T, Morken MH, Strand EA, Mørch K, Coll P, Helgeland L, Langeland N. Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. J Infect. 2007;55:524-530. [PMID: 17964658 DOI: 10.1016/j.jinf.2007.09.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 5.9] [Reference Citation Analysis]
2 Fengming Y, Jianbing W. Biomarkers of inflammatory bowel disease. Dis Markers. 2014;2014:710915. [PMID: 24963213 DOI: 10.1155/2014/710915] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
3 Mazzawi T, Eikrem Ø, Lied GA, Hausken T. Abnormal Uroguanylin Immunoreactive Cells Density in the Duodenum of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Changes following Fecal Microbiota Transplantation. Gastroenterol Res Pract 2020;2020:3520686. [PMID: 32089675 DOI: 10.1155/2020/3520686] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hamilton AC, Auron M. Diarrhea. Hospital Medicine Clinics 2013;2:e227-46. [DOI: 10.1016/j.ehmc.2012.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol 2007;19:567-74. [PMID: 17556903 DOI: 10.1097/MEG.0b013e328058ed76] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
6 Darkoh C, Turnwald BP, Koo HL, Garey KW, Jiang ZD, Aitken SL, DuPont HL. Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol 2014;21:509-17. [PMID: 24477852 DOI: 10.1128/CVI.00770-13] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
7 Usacheva EA, Jin JP, Peterson LR. Host response to Clostridium difficile infection: Diagnostics and detection. J Glob Antimicrob Resist 2016;7:93-101. [PMID: 27693863 DOI: 10.1016/j.jgar.2016.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
8 Schröder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther. 2007;26:1035-1042. [PMID: 17877510 DOI: 10.1111/j.1365-2036.2007.03457.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
9 Rogler G, Aldeguer X, Kruis W, Lasson A, Mittmann U, Nally K, Peyrin-Biroulet L, Schoepfer A, Vatn M, Vavricka S. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis. 2013;7:670-677. [PMID: 23517932 DOI: 10.1016/j.crohns.2013.02.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
10 Sherwood RA. Faecal markers of gastrointestinal inflammation. J Clin Pathol 2012;65:981-5. [DOI: 10.1136/jclinpath-2012-200901] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
11 Dai C, Jiang M, Sun M. Fecal markers in the management of inflammatory bowel disease. Postgraduate Medicine 2018;130:597-606. [DOI: 10.1080/00325481.2018.1503919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Ataseven H, Oztürk ZA, Arhan M, Yüksel O, Köklü S, Ibiş M, Başar O, Yilmaz FM, Yüksel I. Cancer antigen 125 levels in inflammatory bowel diseases. J Clin Lab Anal 2009;23:244-8. [PMID: 19623645 DOI: 10.1002/jcla.20323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
13 Roszak D, Gałęcka M, Cichy W, Szachta P. Determination of faecal inflammatory marker concentration as a noninvasive method of evaluation of pathological activity in children with inflammatory bowel diseases. Adv Med Sci. 2015;60:246-252. [PMID: 25989184 DOI: 10.1016/j.advms.2015.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
14 Romanato G, Scarpa M, Angriman I, Faggian D, Ruffolo C, Marin R, Zambon S, Basato S, Zanoni S, Filosa T, Pilon F, Manzato E. Plasma lipids and inflammation in active inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics 2009;29:298-307. [DOI: 10.1111/j.1365-2036.2008.03886.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
15 Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A, Dobos GJ. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis. 2005;11:1085-1091. [PMID: 16306771 DOI: 10.1097/01.mib.0000187980.08686.18] [Cited by in Crossref: 91] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
16 Mazzawi T, El-Salhy M, Lied GA, Hausken T. The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Front Cell Infect Microbiol 2021;11:524851. [PMID: 34055657 DOI: 10.3389/fcimb.2021.524851] [Reference Citation Analysis]
17 Rubio MG, Amo-Mensah K, Gray JM, Nguyen VQ, Nakat S, Grider D, Love K, Boone JH, Sorrentino D. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol 2019; 10(5): 54-63 [PMID: 31911845 DOI: 10.4291/wjgp.v10.i5.54] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
18 Scarpa M, Bortolami M, Morgan SL, Kotsafti A, Ruffolo C, D’incà R, Bertin E, Polese L, D’amico DF, Sturniolo GC, Angriman I. TGF-β1 and IGF-1 and Anastomotic Recurrence of Crohn’s Disease After Ileo-Colonic Resection. J Gastrointest Surg 2008;12:1981-90. [DOI: 10.1007/s11605-008-0641-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
19 Abraham BP, Kane S. Fecal Markers: Calprotectin and Lactoferrin. Gastroenterology Clinics of North America 2012;41:483-95. [DOI: 10.1016/j.gtc.2012.01.007] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 7.2] [Reference Citation Analysis]
20 Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin Structure and Functions. In: Bösze Z, editor. Bioactive Components of Milk. New York: Springer; 2008. pp. 163-94. [DOI: 10.1007/978-0-387-74087-4_6] [Cited by in Crossref: 145] [Cited by in F6Publishing: 117] [Reference Citation Analysis]
21 Scarpa M, Grillo A, Pozza A, Faggian D, Ruffolo C, Scarpa M, D’Incà R, Plebani M, Sturniolo GC, Castagliuolo I. TLR2 and TLR4 up-regulation and colonization of the ileal mucosa by Clostridiaceae spp. in chronic/relapsing pouchitis. J Surg Res. 2011;169:e145-e154. [PMID: 21601883 DOI: 10.1016/j.jss.2011.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
22 Zhang P, Liu X, Guo A, Xiong J, Fu Y, Zou K. B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease. Dig Dis Sci 2016;61:2608-18. [DOI: 10.1007/s10620-016-4136-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
23 Bennike T, Birkelund S, Stensballe A, Andersen V. Biomarkers in inflammatory bowel diseases: Current status and proteomics identification strategies. World J Gastroenterol 2014; 20(12): 3231-3244 [PMID: 24696607 DOI: 10.3748/wjg.v20.i12.3231] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
24 Abreu MT, Harpaz N. Diagnosis of colitis: making the initial diagnosis. Clin Gastroenterol Hepatol. 2007;5:295-301. [PMID: 17368227 DOI: 10.1016/j.cgh.2006.12.032] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
25 Däbritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol 2014; 20(2): 363-375 [PMID: 24574706 DOI: 10.3748/wjg.v20.i2.363] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
26 Sipponen T, Kärkkäinen P, Savilahti E, Kolho K, Nuutinen H, Turunen U, Färkkilä M. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Alimentary Pharmacology & Therapeutics 2008;28:1221-9. [DOI: 10.1111/j.1365-2036.2008.03835.x] [Cited by in Crossref: 210] [Cited by in F6Publishing: 208] [Article Influence: 16.2] [Reference Citation Analysis]
27 Kushak RI, Buie TM, Murray KF, Newburg DS, Chen C, Nestoridi E, Winter HS. Evaluation of Intestinal Function in Children With Autism and Gastrointestinal Symptoms. J Pediatr Gastroenterol Nutr. 2016;62:687-691. [PMID: 26913756 DOI: 10.1097/mpg.0000000000001174] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 12.7] [Reference Citation Analysis]
28 Rauber C, Awad M, Koschny R, Sauer P, Mehrabi A, Gath P, Weiss K, Gotthardt DN, Rupp C. Biliary calprotectin, lactoferrin and dimeric pyruvate kinase after liver transplantation are associated with biliary damage and graft survival in a case-control study. Clinics and Research in Hepatology and Gastroenterology 2020;44:38-48. [DOI: 10.1016/j.clinre.2019.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Sidhu R, Wilson P, Foye L, Mcalindon ME, Lobo AJ, Morley S, Sanders DS. Can faecal lactoferrin be used as a discriminator for referral for colonoscopy?: Letters to the Editor. Internal Medicine Journal 2010;40:867-8. [DOI: 10.1111/j.1445-5994.2010.02345.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Buderus S, Boone JH, Lentze MJ. Fecal Lactoferrin: Reliable Biomarker for Intestinal Inflammation in Pediatric IBD. Gastroenterol Res Pract. 2015;2015:578527. [PMID: 26089872 DOI: 10.1155/2015/578527] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
31 Ikonomi E, Rothstein RD, Ehrlich AC, Friedenberg FK. Measurement of Fractional Exhaled Nitric Oxide as a Marker of Disease Activity in Inflammatory Bowel Disease. J Gastroenterol Pancreatol Liver Disord 2016;3. [PMID: 27398403 DOI: 10.15226/2374-815X/3/1/00146] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Lundberg JO, Hellström PM, Fagerhol MK, Weitzberg E, Roseth AG. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:96-102. [PMID: 16265127 DOI: 10.1038/ncpgasthep0094] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 3.3] [Reference Citation Analysis]
33 Pfefferkorn MD, Boone JH, Nguyen JT, Juliar BE, Davis MA, Parker KK. Utility of fecal lactoferrin in identifying Crohn disease activity in children. J Pediatr Gastroenterol Nutr. 2010;51:425-428. [PMID: 20562721 DOI: 10.1097/mpg.0b013e3181d67e8f] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
34 Lamb CA, Mohiuddin MK, Gicquel J, Neely D, Bergin FG, Hanson JM, Mansfield JC. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg. 2009;96:663-674. [PMID: 19384912 DOI: 10.1002/bjs.6593] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 8.3] [Reference Citation Analysis]
35 Bar-Gil Shitrit A, Koslowsky B, Livovsky DM, Shitrit D, Paz K, Adar T, Adler SN, Goldin E. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy. Scand J Gastroenterol 2017;52:328-33. [PMID: 27841040 DOI: 10.1080/00365521.2016.1253769] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
36 Hanevik K, Mørch K, Eide GE, Langeland N, Hausken T. Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: a randomized open clinical trial. Scand J Infect Dis 2008;40:517-22. [PMID: 18584540 DOI: 10.1080/00365540701827481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
37 Dotan I. Laboratory Evaluation Including Novel Diagnostic Markers of Inflammatory Bowel Disease. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Boston: Springer US; 2012. pp. 277-85. [DOI: 10.1007/978-1-4614-0998-4_21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, Shand AG, Bartolo DC, Wilson RG, Dunlop MG. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673-678. [PMID: 19262524 DOI: 10.1038/ajg.2008.119] [Cited by in Crossref: 97] [Cited by in F6Publishing: 96] [Article Influence: 8.1] [Reference Citation Analysis]
39 Dale HF, Jensen C, Hausken T, Lied E, Hatlebakk JG, Brønstad I, Hoff DAL, Lied GA. Acute effect of a cod protein hydrolysate on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects: a double-blind crossover trial. Food Nutr Res 2019;63. [PMID: 31692759 DOI: 10.29219/fnr.v63.3507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
40 Ullman TA, Palmon R. The Certain Uncertainty of Measuring Disease Activity in IBD. Journal of Clinical Gastroenterology 2007;41:123-5. [DOI: 10.1097/01.mcg.0000225660.15556.4e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
41 Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci. 2004;49:1036-1039. [PMID: 15309897 DOI: 10.1023/B:DDAS.0000034568.69407.47] [Cited by in Crossref: 61] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
42 Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism--comparisons to typical children and correlation with autism severity. BMC Gastroenterol. 2011;11:22. [PMID: 21410934 DOI: 10.1186/1471-230x-11-22] [Cited by in Crossref: 487] [Cited by in F6Publishing: 256] [Article Influence: 48.7] [Reference Citation Analysis]
43 Deepak P, Fletcher JG, Fidler JL, Bruining DH. Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials. Inflamm Bowel Dis. 2016;22:2280-2288. [PMID: 27508513 DOI: 10.1097/mib.0000000000000845] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
44 Palmon R, Brown SJ, Abreu MT. What is the role and significance of serum and stool biomarkers in the diagnosis of IBD?: . Inflammatory Bowel Diseases 2008;14:S187-9. [DOI: 10.1002/ibd.20714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
45 Skarżyńska E, Żytyńska-daniluk J, Lisowska-myjak B. Meconium lactoferrin levels in neonates: can we predefine normal values? The Journal of Maternal-Fetal & Neonatal Medicine 2016;30:279-83. [DOI: 10.3109/14767058.2016.1171307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Yamada S, Yoshino T, Matsuura M, Minami N, Toyonaga T, Honzawa Y, Tsuji Y, Nakase H. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol. 2014;14:80. [PMID: 24758588 DOI: 10.1186/1471-230x-14-80] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
47 Thorsvik S, Damås JK, Granlund AV, Flo TH, Bergh K, Østvik AE, Sandvik AK. Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease. J Gastroenterol Hepatol 2017;32:128-35. [PMID: 27640344 DOI: 10.1111/jgh.13598] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
48 Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126:1518-1532. [PMID: 15168364 DOI: 10.1053/j.gastro.2004.02.072] [Cited by in Crossref: 233] [Cited by in F6Publishing: 194] [Article Influence: 13.7] [Reference Citation Analysis]
49 Dallas DC, Underwood MA, Zivkovic AM, German JB. Digestion of Protein in Premature and Term Infants. J Nutr Disord Ther 2012;2:112. [PMID: 24744976 DOI: 10.4172/2161-0509.1000112] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
50 Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. J Crohns Colitis 2016;10:786-94. [PMID: 26874351 DOI: 10.1093/ecco-jcc/jjw044] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
51 Nakada N, Mikami T, Horie K, Nagashio R, Sakurai Y, Sanoyama I, Yoshida T, Sada M, Kobayashi K, Sato Y, Okayasu I, Murakumo Y. Expression of CA2 and CA9 carbonic anhydrases in ulcerative colitis and ulcerative colitis-associated colorectal cancer. Pathol Int. 2020;70:523-532. [PMID: 32410301 DOI: 10.1111/pin.12949] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Joishy M, Davies I, Ahmed M, Wassel J, Davies K, Sayers A, Jenkins H. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:48-54. [PMID: 19172123 DOI: 10.1097/mpg.0b013e31816533d3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
53 Magro F, Lopes SI, Lopes J, Portela F, Cotter J, Lopes S, Moreira MJ, Lago P, Peixe P, Albuquerque A, Rodrigues S, Silva MR, Monteiro P, Lopes C, Monteiro L, Macedo G, Veloso L, Camila C, Afonso J, Geboes K, Carneiro F; Portuguese IBD group [GEDII]. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. J Crohns Colitis 2016;10:1407-16. [PMID: 27226417 DOI: 10.1093/ecco-jcc/jjw112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
54 Soubières AA, Poullis A. Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22:2016-2022. [PMID: 27416044 DOI: 10.1097/mib.0000000000000836] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
55 Morken MH, Valeur J, Norin E, Midtvedt T, Nysæter G, Berstad A. Antibiotic or bacterial therapy in post-giardiasis irritable bowel syndrome. Scandinavian Journal of Gastroenterology 2009;44:1296-303. [DOI: 10.3109/00365520903274401] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
56 Ren Z, Gay R, Thomas A, Pae M, Wu D, Logsdon L, Mecsas J, Meydani SN. Effect of age on susceptibility to Salmonella Typhimurium infection in C57BL/6 mice. J Med Microbiol 2009;58:1559-67. [PMID: 19729455 DOI: 10.1099/jmm.0.013250-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
57 Halpert AD. Importance of early diagnosis in patients with irritable bowel syndrome. Postgrad Med. 2010;122:102-111. [PMID: 20203461 DOI: 10.3810/pgm.2010.03.2127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
58 Jensen C, Dale HF, Hausken T, Lied E, Hatlebakk JG, Brønstad I, Lied GA, Hoff DAL. Supplementation with cod protein hydrolysate in older adults: a dose range cross-over study. J Nutr Sci 2019;8:e40. [PMID: 32042407 DOI: 10.1017/jns.2019.37] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
59 Soubières AA, Poullis A. Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 41-50 [PMID: 26855811 DOI: 10.4292/wjgpt.v7.i1.41] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
60 Klimczak K, Lykowska-Szuber L, Eder P, Krela-Kazmierczak I, Stawczyk-Eder K, Szymczak A, Michalak M, Studniarek A, Linke K. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity. Eur J Intern Med. 2015;26:623-627. [PMID: 26198785 DOI: 10.1016/j.ejim.2015.06.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
61 Vara EJ, Svanes C, Skorge TD, Berstad A, Florvaag E, Jarvis D, Omenaas E, Waatevik M, Johannessen A, Lied GA. Functional Gastrointestinal Symptoms Are Associated with Higher Serum Total IgE Levels, but Less Atopic Sensitization. Dig Dis Sci 2016;61:189-97. [DOI: 10.1007/s10620-015-3835-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
62 Dizdar V, Hausken T, Laerum OD, Gilja OH, Langeland N, Hanevik K. Prolonged Duodenal Mucosal Lymphocyte Alterations in Patients With and Without Postinfectious Functional Gastrointestinal Disorders After Giardia Infection. J Infect Dis 2019;220:321-9. [PMID: 30500895 DOI: 10.1093/infdis/jiy690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 Abraham BP, Thirumurthi S. Clinical significance of inflammatory markers. Curr Gastroenterol Rep 2009;11:360-7. [PMID: 19765363 DOI: 10.1007/s11894-009-0055-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
64 Zittan E, Kelly OB, Gralnek IM, Silverberg MS, Hillary Steinhart A. Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity. JGH Open 2018;2:201-6. [PMID: 30483590 DOI: 10.1002/jgh3.12068] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
65 Sidhu R, Wilson P, Wright A, Yau CW, D'Cruz FA, Foye L, Morley S, Lobo AJ, McAlindon ME, Sanders DS. Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther. 2010;31:1365-1370. [PMID: 20331581 DOI: 10.1111/j.1365-2036.2010.04306.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
66 van Langenberg DR, Gearry RB, Wong HL, Ward M, Gibson PR. The potential value of faecal lactoferrin as a screening test in hospitalized patients with diarrhoea. Intern Med J 2010;40:819-27. [PMID: 19849752 DOI: 10.1111/j.1445-5994.2009.02102.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
67 Sipponen T, Savilahti E, Kolho K, Nuutinen H, Turunen U, Färkkilä M. Crohnʼs disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohnʼs disease activity index and endoscopic findings: . Inflammatory Bowel Diseases 2008;14:40-6. [DOI: 10.1002/ibd.20312] [Cited by in Crossref: 303] [Cited by in F6Publishing: 297] [Article Influence: 23.3] [Reference Citation Analysis]
68 Pang T, Leach ST, Katz T, Day AS, Ooi CY. Fecal biomarkers of intestinal health and disease in children. Front Pediatr 2014;2:6. [PMID: 24479111 DOI: 10.3389/fped.2014.00006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
69 Urbanska AM, Karagiannis ED, Guajardo G, Langer RS, Anderson DG. Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer. Biomaterials 2012;33:4752-61. [PMID: 22472433 DOI: 10.1016/j.biomaterials.2012.03.023] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
70 Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144-64. [PMID: 30137275 DOI: 10.1093/ecco-jcc/jjy113] [Cited by in Crossref: 313] [Cited by in F6Publishing: 263] [Article Influence: 156.5] [Reference Citation Analysis]
71 Higgins PDR, Leung J, Schwartz M, Mapili J, Wren PA, Zimmermann EM. The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis: QUANTITATIVE VALIDITY OF THE SCCAI AND SEO INDEX IN UC. Alimentary Pharmacology & Therapeutics 2007;25:333-42. [DOI: 10.1111/j.1365-2036.2006.03205.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
72 Sabra S, Agwa MM. Lactoferrin, a unique molecule with diverse therapeutical and nanotechnological applications. Int J Biol Macromol 2020;164:1046-60. [PMID: 32707283 DOI: 10.1016/j.ijbiomac.2020.07.167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
73 Ali FM, Shehata IH, Abd Elsalam AE, El-ansary M. Diagnostic value of lactoferrin ascitic fluid levels in spontaneous bacterial peritonitis: . Egyptian Liver Journal 2013;3:54-61. [DOI: 10.1097/01.elx.0000427108.01923.3d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis. 2007;13:1374-1378. [PMID: 17577247 DOI: 10.1002/ibd.20214] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
75 Roda G, Caponi A, Benevento M, Nanni P, Mezzanotte L, Belluzzi A, Mayer L, Roda A. New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1239-1246. [PMID: 20127998 DOI: 10.1002/ibd.21212] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
76 Yamamoto T, Shimoyama T, Bamba T, Matsumoto K. Consecutive Monitoring of Fecal Calprotectin and Lactoferrin for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy for Ulcerative Colitis. Am J Gastroenterol. 2015;110:881-887. [PMID: 25916224 DOI: 10.1038/ajg.2015.129] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 5.7] [Reference Citation Analysis]
77 Muthas D, Reznichenko A, Balendran CA, Böttcher G, Clausen IG, Kärrman Mårdh C, Ottosson T, Uddin M, MacDonald TT, Danese S, Berner Hansen M. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol 2017;52:125-35. [PMID: 27610713 DOI: 10.1080/00365521.2016.1235224] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 14.6] [Reference Citation Analysis]
78 Mine S, Takeshima F, Akazawa Y, Matsushima K, Minami H, Yamaguchi N, Ohnita K, Isomoto H, Nakao K. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission. Digestion 2018;97:82-9. [PMID: 29393146 DOI: 10.1159/000484223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
79 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 559] [Article Influence: 227.3] [Reference Citation Analysis]
80 Chakradeo PS, Keshavarzian A, Singh S, Dera AE, Esteban JPG, Lee AA, Burgess HJ, Fogg L, Swanson GR. Chronotype, social jet lag, sleep debt and food timing in inflammatory bowel disease. Sleep Med 2018;52:188-95. [PMID: 30243610 DOI: 10.1016/j.sleep.2018.08.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
81 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990. [PMID: 23040452 DOI: 10.1016/j.crohns.2012.09.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 472] [Article Influence: 59.9] [Reference Citation Analysis]
82 Kornbluth A, Hayes M, Feldman S, Hunt M, Fried-boxt E, Lichtiger S, Legnani P, George J, Young J. Do Guidelines Matter? Implementation of the ACG and AGA Osteoporosis Screening Guidelines in Inflammatory Bowel Disease (IBD) Patients Who Meet the Guidelines' Criteria. Am J Gastroenterol 2006;101:1546-50. [DOI: 10.1111/j.1572-0241.2006.00571.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
83 García Sánchez Mdel V, González R, Iglesias Flores E, Gómez Camacho F, Casais Juanena L, Cerezo Ruiz A, Montero Pérez-Barquero M, Muntané J, de Dios Vega JF. [Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy]. Med Clin (Barc). 2006;127:41-46. [PMID: 16801001 DOI: 10.1157/13090002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
84 Nogueira IM, Miszputen SJ, Ambrogini Jr. O, Artigiani-neto R, Carvente CT, Zanon MI. ASSESSMENT OF THE RESPONSE OF PATIENTS WITH CROHN'S DISEASE TO BIOLOGICAL THERAPY USING NEW NON-INVASIVE MARKERS: lactoferrin and calprotectin. Arq Gastroenterol 2013;50:130-7. [DOI: 10.1590/s0004-28032013000200022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
85 León-Sicairos N, Reyes-López M, Canizalez-Román A, Bermúdez-Cruz RM, Serrano-Luna J, Arroyo R, de la Garza M. Human hololactoferrin: endocytosis and use as an iron source by the parasite Entamoeba histolytica. Microbiology (Reading) 2005;151:3859-71. [PMID: 16339932 DOI: 10.1099/mic.0.28121-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
86 Lai HH, Chiu CH, Kong MS, Chang CJ, Chen CC. Probiotic Lactobacillus casei: Effective for Managing Childhood Diarrhea by Altering Gut Microbiota and Attenuating Fecal Inflammatory Markers. Nutrients 2019;11:E1150. [PMID: 31126062 DOI: 10.3390/nu11051150] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
87 Larsen A, Bjørge B, Klementsen B, Helgeland L, Wentzel-Larsen T, Fagerhol MK, Hovdenak N, Dahl O. Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy. Acta Oncol. 2007;46:639-650. [PMID: 17562440 DOI: 10.1080/02841860601099241] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
88 León-sicairos N, Ordaz-pichardo C, Carrero JC, Garza MDL. Lactoferrin in the Battle against Intestinal Parasites: A Review. In: Khater H, Govindarajan M, Benelli G, editors. Natural Remedies in the Fight Against Parasites. InTech; 2017. [DOI: 10.5772/66819] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
89 Mørch K, Hanevik K, Rortveit G, Wensaas KA, Eide GE, Hausken T, Langeland N. Severity of Giardia infection associated with post-infectious fatigue and abdominal symptoms two years after. BMC Infect Dis. 2009;9:206. [PMID: 20003489 DOI: 10.1186/1471-2334-9-206] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
90 García-Montoya IA, Cendón TS, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin a multiple bioactive protein: an overview. Biochim Biophys Acta 2012;1820:226-36. [PMID: 21726601 DOI: 10.1016/j.bbagen.2011.06.018] [Cited by in Crossref: 221] [Cited by in F6Publishing: 187] [Article Influence: 22.1] [Reference Citation Analysis]
91 Valeur J, Øines E, Helvik Morken M, Juul Holst J, Berstad A. Plasma glucagon-like peptide 1 and peptide YY levels are not altered in symptomatic fructose-sorbitol malabsorption. Scandinavian Journal of Gastroenterology 2009;43:1212-8. [DOI: 10.1080/00365520802116448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
92 Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247-55. [PMID: 17217454 DOI: 10.1111/j.1365-2036.2006.03184.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 6.8] [Reference Citation Analysis]
93 Judd TA, Day AS, Lemberg DA, Turner D, Leach ST. Update of fecal markers of inflammation in inflammatory bowel disease: Fecal markers of inflammation update. Journal of Gastroenterology and Hepatology 2011;26:1493-9. [DOI: 10.1111/j.1440-1746.2011.06846.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
94 Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1746-1754. [PMID: 19363798 DOI: 10.1002/ibd.20920] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
95 Probert F, Walsh A, Jagielowicz M, Yeo T, Claridge TDW, Simmons A, Travis S, Anthony DC. Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis. J Crohns Colitis 2018;12:1326-37. [PMID: 30016408 DOI: 10.1093/ecco-jcc/jjy101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
96 Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474-1482. [PMID: 22929759 DOI: 10.1038/ajg.2012.260] [Cited by in Crossref: 318] [Cited by in F6Publishing: 290] [Article Influence: 35.3] [Reference Citation Analysis]
97 Gearry RB. Faecal testing in inflammatory bowel disease. In: Fraser A, Hibi T, Gibson PR, Oian J-, Schölmerich J, editors. Emerging Issues in Inflammatory Bowel Diseases. Dordrecht: Springer Netherlands; 2007. pp. 135-48. [DOI: 10.1007/978-1-4020-5702-1_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Opintan JA, Newman MJ, Ayeh-Kumi PF, Affrim R, Gepi-Attee R, Sevilleja JE, Roche JK, Nataro JP, Warren CA, Guerrant RL. Pediatric diarrhea in southern Ghana: etiology and association with intestinal inflammation and malnutrition. Am J Trop Med Hyg 2010;83:936-43. [PMID: 20889896 DOI: 10.4269/ajtmh.2010.09-0792] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
99 Zhou R, Qiu P, Wang H, Yang H, Yang X, Ye M, Wang F, Zhao Q. Identification of microRNA-16-5p and microRNA-21-5p in feces as potential noninvasive biomarkers for inflammatory bowel disease. Aging (Albany NY) 2021;13:4634-46. [PMID: 33535181 DOI: 10.18632/aging.202428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41:56-66. [PMID: 18602356 DOI: 10.1016/j.dld.2008.05.008] [Cited by in Crossref: 140] [Cited by in F6Publishing: 143] [Article Influence: 10.8] [Reference Citation Analysis]
101 Greaves ML, Pochapin M. Asymptomatic ileitis: past, present, and future. J Clin Gastroenterol 2006;40:281-5. [PMID: 16633097 DOI: 10.1097/01.mcg.0000210104.59370.66] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
102 Bousvaros A. Mucosal healing in children with Crohn’s disease: appropriate therapeutic goal or medical overkill? Inflamm Bowel Dis. 2004;10:481-483. [PMID: 15475762 DOI: 10.1097/00054725-200407000-00025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
103 Saps M, Di Lorenzo C. Diagnosing and Managing Functional Symptoms in the Child with Inflammatory Bowel Disease: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:S760-2. [DOI: 10.1097/00005176-200406003-00022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
104 Lim M, Gonsalves S, Thekkinkattil D, Seedat S, Finan P, Sagar P, Burke D. The assessment of a rapid noninvasive immunochromatographic assay test for fecal lactoferrin in patients with suspected inflammation of the ileal pouch. Dis Colon Rectum 2008;51:96-9. [PMID: 18085334 DOI: 10.1007/s10350-007-9151-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
105 Jin P, Wang K, Huang C, Nice EC. Mining the fecal proteome: from biomarkers to personalised medicine. Expert Rev Proteomics 2017;14:445-59. [PMID: 28361558 DOI: 10.1080/14789450.2017.1314786] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
106 Lee K. Fecal Biomarkers in Inflammatory Bowel Disease. Intest Res 2013;11:73. [DOI: 10.5217/ir.2013.11.2.73] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
107 Ruffolo C, Scarpa M, Faggian D, Basso D, D’Incà R, Plebani M, Sturniolo GC, Bassi N, Angriman I. Subclinical intestinal inflammation in patients with Crohn’s disease following bowel resection: a smoldering fire. J Gastrointest Surg. 2010;14:24-31. [PMID: 19902313 DOI: 10.1007/s11605-009-1070-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
108 Carrasco-Labra A, Lytvyn L, Falck-Ytter Y, Surawicz CM, Chey WD. AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). Gastroenterology. 2019;157:859-880. [PMID: 31351880 DOI: 10.1053/j.gastro.2019.06.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
109 Angriman I, Scarpa M, D’Incà R, Basso D, Ruffolo C, Polese L, Sturniolo GC, D’Amico DF, Plebani M. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63-68. [PMID: 17368600 DOI: 10.1016/j.cca.2007.02.025] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 5.0] [Reference Citation Analysis]
110 Zittan E, Kelly OB, Kirsch R, Milgrom R, Burns J, Nguyen GC, Croitoru K, Van Assche G, Silverberg MS, Steinhart AH. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease. Inflamm Bowel Dis. 2016;22:623-630. [PMID: 26829408 DOI: 10.1097/mib.0000000000000652] [Cited by in Crossref: 93] [Cited by in F6Publishing: 35] [Article Influence: 18.6] [Reference Citation Analysis]
111 Leach ST, Nahidi L, Tilakaratne S, Day AS, Lemberg DA. Development and assessment of a modified Pediatric Crohn Disease Activity Index. J Pediatr Gastroenterol Nutr. 2010;51:232-236. [PMID: 20479686 DOI: 10.1097/mpg.0b013e3181d13609] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
112 Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450-455. [PMID: 15795593 DOI: 10.1097/01.mpg.0000154657.08994.94] [Cited by in Crossref: 96] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
113 Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-1826. e2. [PMID: 21530748 DOI: 10.1053/j.gastro.2010.11.058] [Cited by in Crossref: 268] [Cited by in F6Publishing: 238] [Article Influence: 26.8] [Reference Citation Analysis]
114 Pasha SF, Leighton JA. Novel Techniques in the Diagnosis of Inflammatory Bowel Disease. Inflammatory Bowel Disease. 2011;231-253. [PMID: 18240283 DOI: 10.1007/978-1-60327-433-3_15] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Cepon-Robins TJ. Measuring attack on self: The need for field-friendly methods development and research on autoimmunity in human biology. Am J Hum Biol 2020. [PMID: 33289250 DOI: 10.1002/ajhb.23544] [Reference Citation Analysis]
116 Furman DL, Cash BD. The role of diagnostic testing in irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40:105-119. [PMID: 21333903 DOI: 10.1016/j.gtc.2010.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
117 Gururangan K, Holubar MK. A Case of Postoperative Methicillin-Resistant Staphylococcus aureus Enterocolitis in an 81-Year-Old Man and Review of the Literature. Am J Case Rep 2020;21:e922521. [PMID: 32989210 DOI: 10.12659/AJCR.922521] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Czub E, Herzig KH, Szaflarska-Popawska A, Kiehne K, Socha P, Woś H, Kamińska B, Błaszczyński M, Cichy W, Bała G, Brodzicki J, Grzybowska-Chlebowczyk U, Walkowiak J. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol 2007;42:1147-50. [PMID: 17852864 DOI: 10.1080/00365520701320513] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
119 Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis. 2014;29:485-491. [PMID: 24343276 DOI: 10.1007/s00384-013-1817-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
120 Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013;38:77-97. [DOI: 10.1111/apt.12345] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
121 Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis. 2008;14:1392-1398. [PMID: 18484671 DOI: 10.1002/ibd.20490] [Cited by in Crossref: 162] [Cited by in F6Publishing: 156] [Article Influence: 13.5] [Reference Citation Analysis]
122 Khanna R, Narula N, Feagan BG. The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:1619-23. [PMID: 29846593 DOI: 10.1093/ibd/izy195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
123 Larsen A, Hovdenak N, Karlsdottir Á, Wentzel-larsen T, Dahl O, Fagerhol MK. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. Scandinavian Journal of Gastroenterology 2009;39:1113-8. [DOI: 10.1080/00365520410003614] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
124 Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, Rufo PA. Fecal Lactoferrin Is a Sensitive and Specific Marker of Disease Activity in Children and Young Adults With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2007;44:414-22. [DOI: 10.1097/mpg.0b013e3180308d8e] [Cited by in Crossref: 89] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
125 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Keenan JI, Leach S, Burgess L, Aitchison A, Gorelik A. Comparison of Fecal Inflammatory Markers in Crohn's Disease. Inflamm Bowel Dis. 2016;22:1086-1094. [PMID: 26818420 DOI: 10.1097/MIB.0000000000000671] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
126 Fischer R, Debbabi H, Dubarry M, Boyaka P, Tomé D. Regulation of physiological and pathological Th1 and Th2 responses by lactoferrin. Biochem Cell Biol. 2006;84:303-311. [PMID: 16936801 DOI: 10.1139/o06-058] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
127 Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1440-1444. [PMID: 17852860 DOI: 10.1080/00365520701427094] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
128 Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8:23-36. [PMID: 25553077 DOI: 10.1177/1756283x14553384] [Cited by in Crossref: 95] [Cited by in F6Publishing: 37] [Article Influence: 15.8] [Reference Citation Analysis]
129 de Bruyn M, Vandooren J, Ugarte-berzal E, Arijs I, Vermeire S, Opdenakker G. The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases. Critical Reviews in Biochemistry and Molecular Biology 2016;51:295-358. [DOI: 10.1080/10409238.2016.1199535] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
130 Ellermann M, Arthur JC. Siderophore-mediated iron acquisition and modulation of host-bacterial interactions. Free Radic Biol Med 2017;105:68-78. [PMID: 27780750 DOI: 10.1016/j.freeradbiomed.2016.10.489] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 10.6] [Reference Citation Analysis]
131 Kyriakidi KS, Tsianos VE, Karvounis E, Christodoulou DK, Katsanos KH, Tsianos EV. Neutrophil anti-neutrophil cytoplasmic autoantibody proteins: bactericidal increasing protein, lactoferrin, cathepsin, and elastase as serological markers of inflammatory bowel and other diseases. Ann Gastroenterol 2016;29:258-67. [PMID: 27366026 DOI: 10.20524/aog.2016.0028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
132 Ayling RM. New faecal tests in gastroenterology. Ann Clin Biochem. 2012;49:44-54. [PMID: 22113956 DOI: 10.1258/acb.2011.011150] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
133 Vieira A, Fang CB, Rolim EG, Klug WA, Steinwurz F, Rossini LG, Candelária PA. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes. 2009;2:221. [PMID: 19874614 DOI: 10.1186/1756-0500-2-221] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 6.2] [Reference Citation Analysis]
134 Zimmerman LA, Srinath AI, Goyal A, Bousvaros A, Ducharme P, Szigethy E, Nurko S. The overlap of functional abdominal pain in pediatric Crohn's disease. Inflamm Bowel Dis. 2013;19:826-831. [PMID: 23407043 DOI: 10.1097/mib.0b013e3182802a0a] [Cited by in Crossref: 49] [Cited by in F6Publishing: 17] [Article Influence: 6.1] [Reference Citation Analysis]
135 Bennike TB, Carlsen TG, Ellingsen T, Bonderup OK, Glerup H, Bøgsted M, Christiansen G, Birkelund S, Stensballe A, Andersen V. Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies. Inflamm Bowel Dis. 2015;21:2052-2067. [PMID: 25993694 DOI: 10.1097/mib.0000000000000460] [Cited by in Crossref: 74] [Cited by in F6Publishing: 35] [Article Influence: 14.8] [Reference Citation Analysis]
136 Mazzawi T, Hausken T, Hov JR, Valeur J, Sangnes DA, El-Salhy M, Gilja OH, Hatlebakk JG, Lied GA. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scand J Gastroenterol 2019;54:690-9. [PMID: 31190584 DOI: 10.1080/00365521.2019.1624815] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
137 Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices. Am J Gastroenterol 2008;103:162-9. [DOI: 10.1111/j.1572-0241.2007.01556.x] [Cited by in Crossref: 377] [Cited by in F6Publishing: 363] [Article Influence: 29.0] [Reference Citation Analysis]
138 Masoodi I, Tijjani BM, Wani H, Hassan NS, Khan AB, Hussain S. Biomarkers in the management of ulcerative colitis: a brief review. Ger Med Sci. 2011;9:Doc03. [PMID: 21394194 DOI: 10.3205/000126] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
139 Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci. 2004;49:1036-1039. [PMID: 15309897 DOI: 10.1023/b:das.0000034568.69407.47] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Lind R, Berstad A, Hatlebakk J, Valeur J. Chronic fatigue in patients with unexplained self-reported food hypersensitivity and irritable bowel syndrome: validation of a Norwegian translation of the Fatigue Impact Scale. Clin Exp Gastroenterol. 2013;6:101-107. [PMID: 23869173 DOI: 10.2147/ceg.s45760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
141 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, van Assche G. [Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]. Rev Gastroenterol Mex 2014;79:263-89. [PMID: 25487134 DOI: 10.1016/j.rgmx.2014.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
142 Fukushima N, Koopmann J, Sato N, Prasad N, Carvalho R, Leach SD, Hruban RH, Goggins M. Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol. 2005;18:779-787. [PMID: 15791284 DOI: 10.1038/modpathol.3800337] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
143 Chilton CH, Crowther GS, Śpiewak K, Brindell M, Singh G, Wilcox MH, Monaghan TM. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection. J Antimicrob Chemother 2016;71:975-85. [PMID: 26759363 DOI: 10.1093/jac/dkv452] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
144 Larsen T, Hausken T, Otteraaen Ystad S, Hovdenak N, Mueller B, Lied GA. Does the low FODMAP diet improve symptoms of radiation-induced enteropathy? A pilot study. Scand J Gastroenterol 2018;53:541-8. [PMID: 29113519 DOI: 10.1080/00365521.2017.1397186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
145 Mendoza J, Abreu M. Biological markers in inflammatory bowel disease: Practical consideration for clinicians. Gastroentérologie Clinique et Biologique 2009;33:S158-73. [DOI: 10.1016/s0399-8320(09)73151-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
146 Sipponen T, Björkesten CG, Färkkilä M, Nuutinen H, Savilahti E, Kolho KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol. 2010;45:325-331. [PMID: 20034360 DOI: 10.3109/00365520903483650] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 10.0] [Reference Citation Analysis]
147 Chen CC, Chang CJ, Lin TY, Lai MW, Chao HC, Kong MS. Usefulness of fecal lactoferrin in predicting and monitoring the clinical severity of infectious diarrhea. World J Gastroenterol 2011; 17(37): 4218-4224 [PMID: 22072854 DOI: 10.3748/wjg.v17.i37.4218] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
148 Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, Ardid D. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012;36:1009-31. [DOI: 10.1111/apt.12080] [Cited by in Crossref: 125] [Cited by in F6Publishing: 122] [Article Influence: 13.9] [Reference Citation Analysis]
149 Scarpa M, Pilon F, Pengo V, Romanato G, Ruffolo C, Erroi F, Elisa B, Frego M, Ossi E, Manzato E. Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough? World J Surg. 2010;34:1629-1636. [PMID: 20177681 DOI: 10.1007/s00268-010-0490-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
150 Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res. 2012;159:313-325. [PMID: 22424434 DOI: 10.1016/j.trsl.2012.01.001] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 12.9] [Reference Citation Analysis]
151 Parsi MA, Saadeh SN, Zein NN, Davis GL, Lopez R, Boone J, Lepe MR, Guo L, Ashfaq M, Klintmalm G. Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology. 2008;135:803-807. [PMID: 18590731 DOI: 10.1053/j.gastro.2008.05.045] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
152 Barnes EL, Burakoff R. New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflamm Bowel Dis 2016;22:2956-65. [PMID: 27763951 DOI: 10.1097/MIB.0000000000000903] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 5.7] [Reference Citation Analysis]
153 Gisbert JP, González-Lama Y, Maté J. [Role of biological markers in inflammatory bowel disease]. Gastroenterol Hepatol. 2007;30:117-129. [PMID: 17374324 DOI: 10.1157/13100073] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
154 Stadnyk AW, Carrigan SO, Otley AR. Neutrophil Transintestinal Epithelial Migration to CXCR2 Ligands Is Regulated by Adenosine. Journal of Pediatric Gastroenterology & Nutrition 2012;54:414-21. [DOI: 10.1097/mpg.0b013e3182318d13] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
155 Gupta A, Derbes C, Sellin J. Clinical Indications of the Use of Antineutrophil Cytoplasmic Antibodies and Anti-Saccharomyces cerevisiae Antibodies in the Evaluation of Inflammatory Bowel Disease at an Academic Medical Center: . Inflammatory Bowel Diseases 2005;11:898-902. [DOI: 10.1097/01.mib.0000182866.89895.3f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
156 Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E; for the European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Journal of Crohn's and Colitis 2010;4:7-27. [DOI: 10.1016/j.crohns.2009.12.003] [Cited by in Crossref: 762] [Cited by in F6Publishing: 680] [Article Influence: 69.3] [Reference Citation Analysis]
157 Zhang H, Zeng Z, Mukherjee A, Shen B. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn. 2018;18:867-886. [PMID: 30152711 DOI: 10.1080/14737159.2018.1516549] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
158 Lazaridis N, Germanidis G. Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann Gastroenterol 2018;31:171-87. [PMID: 29507464 DOI: 10.20524/aog.2018.0229] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
159 Turkay C, Kasapoglu B. Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update. Clinics (Sao Paulo). 2010;65:221-231. [PMID: 20186307 DOI: 10.1590/S1807-59322010000200015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
160 Hanafy AS, Monir MH, Abdel Malak H, Desoky Aiad M. A Simple Noninvasive Score Predicts Disease Activity and Deep Remission in Ulcerative Colitis. Inflamm Intest Dis 2018;3:16-24. [PMID: 30505838 DOI: 10.1159/000490795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
161 Hanauer SB. Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nat Rev Gastroenterol Hepatol 2004;1:26-31. [DOI: 10.1038/ncpgasthep0031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
162 Dufour V, Millon L, Faucher JF, Bard E, Robinet E, Piarroux R, Vuitton DA, Meillet D. Effects of a short-course of amoxicillin/clavulanic acid on systemic and mucosal immunity in healthy adult humans. Int Immunopharmacol 2005;5:917-28. [PMID: 15778127 DOI: 10.1016/j.intimp.2005.01.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
163 Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021;116:17-44. [DOI: 10.14309/ajg.0000000000001036] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 47.0] [Reference Citation Analysis]
164 Lind R, Lied GA, Lillestøl K, Valeur J, Berstad A. Do psychological factors predict symptom severity in patients with subjective food hypersensitivity? Scand J Gastroenterol 2010;45:835-43. [PMID: 20433401 DOI: 10.3109/00365521003797213] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
165 Jiang W, Li X. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Mol Diagn Ther 2015;19:141-58. [DOI: 10.1007/s40291-015-0142-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
166 Camilleri M. Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease. Gut. 2011;60:425-428. [PMID: 21292684 DOI: 10.1136/gut.2010.234583] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
167 Scarpa M, D’Incà R, Basso D, Ruffolo C, Polese L, Bertin E, Luise A, Frego M, Plebani M, Sturniolo GC. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn’s disease. Dis Colon Rectum. 2007;50:861-869. [PMID: 17473939 DOI: 10.1007/s10350-007-0225-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 5.3] [Reference Citation Analysis]
168 Spadaro M, Caorsi C, Ceruti P, Varadhachary A, Forni G, Pericle F, Giovarelli M. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J 2008;22:2747-57. [PMID: 18364398 DOI: 10.1096/fj.07-098038] [Cited by in Crossref: 96] [Cited by in F6Publishing: 84] [Article Influence: 7.4] [Reference Citation Analysis]
169 Yamamoto T. The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn’s disease. United European Gastroenterol J. 2015;3:5-10. [PMID: 25653853 DOI: 10.1177/2050640614558106] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
170 Hanevik K, Kristoffersen EK, Sørnes S, Mørch K, Næss H, Rivenes AC, Bødtker JE, Hausken T, Langeland N. Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome. BMC Infect Dis 2012;12:258. [PMID: 23061432 DOI: 10.1186/1471-2334-12-258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
171 Zhou XL, Xu W, Tang XX, Luo LS, Tu JF, Zhang CJ, Xu X, Wu QD, Pan WS. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol. 2014;14:121. [PMID: 25002150 DOI: 10.1186/1471-230x-14-121] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
172 Yang DH, Yang SK, Park SH, Lee HS, Boo SJ, Park JH, Na SY, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ. Usefulness of C-reactive protein as a disease activity marker in Crohn's disease according to the location of disease. Gut Liver 2015;9:80-6. [PMID: 25170056 DOI: 10.5009/gnl13424] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
173 Dale HF, Hatlebakk JG, Hovdenak N, Ystad SO, Lied GA. The effect of a controlled gluten challenge in a group of patients with suspected non-coeliac gluten sensitivity: A randomized, double-blind placebo-controlled challenge. Neurogastroenterol Motil 2018. [PMID: 29542844 DOI: 10.1111/nmo.13332] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
174 Parsi MA, Ellis JJ, Lashner BA. Cost-effectiveness of Quantitative Fecal Lactoferrin Assay for Diagnosis of Symptomatic Patients With Ileal Pouch-anal Anastomosis. Journal of Clinical Gastroenterology 2008;42:799-805. [DOI: 10.1097/mcg.0b013e318074fdfe] [Cited by in Crossref: 14] [Article Influence: 1.1] [Reference Citation Analysis]
175 Legrand D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol 2012;90:252-68. [PMID: 22136726 DOI: 10.1139/o11-056] [Cited by in Crossref: 101] [Cited by in F6Publishing: 104] [Article Influence: 10.1] [Reference Citation Analysis]
176 Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut. 2007;56:1706-1713. [PMID: 17675327 DOI: 10.1136/gut.2006.113431] [Cited by in Crossref: 128] [Cited by in F6Publishing: 130] [Article Influence: 9.1] [Reference Citation Analysis]
177 D’incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429-37. [DOI: 10.1007/s00384-006-0159-9] [Cited by in Crossref: 135] [Cited by in F6Publishing: 138] [Article Influence: 9.0] [Reference Citation Analysis]
178 Burri E, Manz M, Rothen C, Rossi L, Beglinger C, Lehmann FS. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clin Chim Acta. 2013;416:41-47. [PMID: 23178549 DOI: 10.1016/j.cca.2012.11.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
179 Shane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, Langley JM, Wanke C, Warren CA, Cheng AC, Cantey J, Pickering LK. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017;65:e45-e80. [PMID: 29053792 DOI: 10.1093/cid/cix669] [Cited by in Crossref: 144] [Cited by in F6Publishing: 100] [Article Influence: 48.0] [Reference Citation Analysis]
180 Zhang Y, Lu C, Zhang J. Lactoferrin and Its Detection Methods: A Review. Nutrients 2021;13:2492. [PMID: 34444652 DOI: 10.3390/nu13082492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
181 Miranda C, Taqatqa A, Chapa-rodriguez A, Holton JP, Awad SM. The Use of Fecal Calprotectin Levels in the Fontan population. Pediatr Cardiol 2018;39:591-4. [DOI: 10.1007/s00246-017-1796-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
182 Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn WJ. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008;6:1218-1224. [PMID: 18799360 DOI: 10.1016/j.cgh.2008.06.010] [Cited by in Crossref: 264] [Cited by in F6Publishing: 237] [Article Influence: 20.3] [Reference Citation Analysis]
183 Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis. 2008;2:1-23. [PMID: 21172194 DOI: 10.1016/j.crohns.2007.11.001] [Cited by in Crossref: 353] [Cited by in F6Publishing: 324] [Article Influence: 27.2] [Reference Citation Analysis]
184 Gubatan J, Holman DR, Puntasecca CJ, Polevoi D, Rubin SJ, Rogalla S. Antimicrobial peptides and the gut microbiome in inflammatory bowel disease. World J Gastroenterol 2021; 27(43): 7402-7422 [DOI: 10.3748/wjg.v27.i43.7402] [Reference Citation Analysis]
185 Boone JH, DiPersio JR, Tan MJ, Salstrom SJ, Wickham KN, Carman RJ, Totty HR, Albert RE, Lyerly DM. Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis. 2013;32:1517-1523. [PMID: 23771554 DOI: 10.1007/s10096-013-1905-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
186 Moniuszko A, Wiśniewska A, Rydzewska G. Biomarkers in management of inflammatory bowel disease. Prz Gastroenterol. 2013;8:275-283. [PMID: 24868269 DOI: 10.5114/pg.2013.38728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
187 Lamb CA, Mansfield JC. Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease. Frontline Gastroenterol. 2011;2:13-18. [PMID: 23904968 DOI: 10.1136/fg.2010.001362] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
188 Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs 2006;8:279-302. [PMID: 17037946 DOI: 10.2165/00148581-200608050-00002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
189 Gonsalves S, Lim M, Finan P, Sagar P, Burke D. Fecal Lactoferrin: A Noninvasive Fecal Biomarker for the Diagnosis and Surveillance of Pouchitis. Diseases of the Colon & Rectum 2013;56:733-7. [DOI: 10.1097/dcr.0b013e318280194a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
190 Berentsen B, Nagaraja BH, Teige EP, Lied GA, Lundervold AJ, Lundervold K, Steinsvik EK, Hillestad ER, Valeur J, Brønstad I, Gilja OH, Osnes B, Hatlebakk JG, Haász J, Labus J, Gupta A, Mayer EA, Benitez-Páez A, Sanz Y, Lundervold A, Hausken T. Study protocol of the Bergen brain-gut-microbiota-axis study: A prospective case-report characterization and dietary intervention study to evaluate the effects of microbiota alterations on cognition and anatomical and functional brain connectivity in patients with irritable bowel syndrome. Medicine (Baltimore) 2020;99:e21950. [PMID: 32925728 DOI: 10.1097/MD.0000000000021950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
191 Scarpa M, Bortolami M, Morgan SL, Kotsafti A, Ferraro S, Ruffolo C, D'incà R, Polese L, Barollo M, D'amico DF, Sturniolo GC, Angriman I. TGF-β1 and IGF-1 Production and Recurrence of Crohn's Disease After Ileo-Colonic Resection. Journal of Surgical Research 2009;152:26-34. [DOI: 10.1016/j.jss.2008.04.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
192 Dale HF, Jensen C, Hausken T, Lied E, Hatlebakk JG, Brønstad I, Lihaug Hoff DA, Lied GA. Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial. J Nutr Sci 2018;7:e33. [PMID: 30524707 DOI: 10.1017/jns.2018.23] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
193 Mehta V, Gupta A, Mahajan R, Narang V, Midha V, Sood N, Kaur H, Kaur K, Sood A. Symptomatic isolated terminal ileal ulcers: etiology and clinical significance. Endosc Int Open 2017;5:E539-46. [PMID: 28670609 DOI: 10.1055/s-0043-100688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
194 Hirata I, Hoshimoto M, Saito O, Kayazawa M, Nishikawa T, Murano M, Toshina K, Wang FY, Matsuse R. Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. World J Gastroenterol 2007; 13(10): 1569-1574 [PMID: 17461450 DOI: 10.3748/wjg.v13.i10.1569] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
195 Beniwal P, Harrell L. The status of diagnostic markers for inflammatory bowel disease. Curr Gastroenterol Rep. 2010;12:479-484. [PMID: 20890737 DOI: 10.1007/s11894-010-0145-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
196 Costa F, Mumolo MG, Marchi S, Bellini M. Differential diagnosis between functional and organic intestinal disorders: Is there a role for non-invasive tests? World J Gastroenterol 2007; 13(2): 219-223 [PMID: 17226899 DOI: 10.3748/wjg.v13.i2.219] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
197 Archbald-Pannone LR. Quantitative Fecal Lactoferrin as a Biomarker for Severe Clostridium difficile Infection in Hospitalized Patients. J Geriatr Palliat Care 2014;2:3. [PMID: 25401164 DOI: 10.13188/2373-1133.1000006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
198 Viennois E, Zhao Y, Merlin D. Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine. Inflamm Bowel Dis. 2015;21:2467-2474. [PMID: 25985250 DOI: 10.1097/mib.0000000000000444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
199 Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum. 2007;50:1697-1706. [PMID: 17762964 DOI: 10.1007/s10350-007-0303-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
200 Masoodi I, Kochhar R, Dutta U, Vaishnavi C, Prasad KK, Vaiphei K, Kaur S, Singh K. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. J Gastroenterol Hepatol. 2009;24:1768-1774. [PMID: 20136960 DOI: 10.1111/j.1440-1746.2009.06048.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
201 Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum. 2008;51:1283-1291. [PMID: 18543035 DOI: 10.1007/s10350-008-9310-8] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
202 Morken MH, Nysaeter G, Strand EA, Hausken T, Berstad A. Lactulose breath test results in patients with persistent abdominal symptoms following Giardia lamblia infection. Scandinavian Journal of Gastroenterology 2009;43:141-5. [DOI: 10.1080/00365520701673960] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
203 Otten CM, Kok L, Witteman BJ, Baumgarten R, Kampman E, Moons KG, de Wit NJ. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med. 2008;46:1275-1280. [PMID: 18597588 DOI: 10.1515/cclm.2008.246] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
204 Celi P, Verlhac V, Pérez Calvo E, Schmeisser J, Kluenter A. Biomarkers of gastrointestinal functionality in animal nutrition and health. Animal Feed Science and Technology 2019;250:9-31. [DOI: 10.1016/j.anifeedsci.2018.07.012] [Cited by in Crossref: 52] [Cited by in F6Publishing: 9] [Article Influence: 26.0] [Reference Citation Analysis]
205 Mizusawa M, Carroll KC. Advances and required improvements in methods to diagnosing Clostridioides difficile infections in the healthcare setting. Expert Rev Mol Diagn 2021;21:311-21. [PMID: 33682564 DOI: 10.1080/14737159.2021.1900737] [Reference Citation Analysis]
206 Caccaro R, D’incà R, Martinato M, Pont ED, Pathak S, Frigo AC, Sturniolo GC. Fecal lactoferrin and intestinal permeability are effective non-invasive markers in the diagnostic work-up of chronic diarrhea. Biometals 2014;27:1069-76. [DOI: 10.1007/s10534-014-9745-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
207 León-Sicairos N, Reyes-López M, Ordaz-Pichardo C, de la Garza M. Microbicidal action of lactoferrin and lactoferricin and their synergistic effect with metronidazole in Entamoeba histolytica. Biochem Cell Biol 2006;84:327-36. [PMID: 16936803 DOI: 10.1139/o06-060] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
208 Sagawa T, Kakizaki S, Tomizawa T, Nakayama T, Tanaka H, Tojima H, Sato K, Kusano M, Okamura S, Yamada M. Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy. Colorectal Dis 2016;18:696-702. [PMID: 26748553 DOI: 10.1111/codi.13258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
209 Schiller LR, Sellin JH. Diarrhea. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 211-232.e4. [DOI: 10.1016/b978-1-4160-6189-2.00015-9] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]
210 Garolla A, D’Incà R, Checchin D, Biagioli A, De Toni L, Nicoletti V, Scarpa M, Bolzonello E, Sturniolo GC, Foresta C. Reduced endothelial progenitor cell number and function in inflammatory bowel disease: a possible link to the pathogenesis. Am J Gastroenterol. 2009;104:2500-2507. [PMID: 19568231 DOI: 10.1038/ajg.2009.332] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
211 Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32-39. [PMID: 17924558 DOI: 10.1002/ibd.20275] [Cited by in Crossref: 168] [Cited by in F6Publishing: 165] [Article Influence: 12.9] [Reference Citation Analysis]
212 Burbige EJ. Irritable bowel syndrome: diagnostic approaches in clinical practice. Clin Exp Gastroenterol. 2010;3:127-137. [PMID: 21694856 DOI: 10.2147/ceg.s12596] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
213 Mainardi E, Villanacci V, Bassotti G, Liserre B, Rossi E, Incardona P, Falchetti D, Tonegatti L, Montanelli A, Barabino A, Coccia C, Gambini C. Diagnostic Value of Serological Assays in Pediatric Inflammatory Bowel Disorders. Digestion 2007;75:210-4. [DOI: 10.1159/000109928] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
214 Stakenborg M, Verstockt B, Meroni E, Goverse G, De Simone V, Verstockt S, Di Matteo M, Czarnewski P, Villablanca EJ, Ferrante M, Boeckxstaens GE, Mazzone M, Vermeire S, Matteoli G. Neutrophilic HGF-MET signaling exacerbates intestinal inflammation. J Crohns Colitis 2020:jjaa121. [PMID: 32556102 DOI: 10.1093/ecco-jcc/jjaa121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
215 Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: A prospective pilot study. United European Gastroenterol J. 2013;1:368-374. [PMID: 24917985 DOI: 10.1177/2050640613501818] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
216 Pisani LF, Moriggi M, Gelfi C, Vecchi M, Pastorelli L. Proteomic insights on the metabolism in inflammatory bowel disease. World J Gastroenterol 2020; 26(7): 696-705 [PMID: 32116417 DOI: 10.3748/wjg.v26.i7.696] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Nemakayala DR, Cash BD. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go? Curr Opin Gastroenterol 2019;35:58-62. [PMID: 30407259 DOI: 10.1097/MOG.0000000000000493] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
218 Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010;47:259-63. [DOI: 10.1258/acb.2009.009061] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 5.3] [Reference Citation Analysis]
219 Mazzawi T, Lied GA, Sangnes DA, El-Salhy M, Hov JR, Gilja OH, Hatlebakk JG, Hausken T. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLoS One 2018;13:e0194904. [PMID: 30427836 DOI: 10.1371/journal.pone.0194904] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
220 Karav S, German JB, Rouquié C, Le Parc A, Barile D. Studying Lactoferrin N-Glycosylation. Int J Mol Sci 2017;18:E870. [PMID: 28425960 DOI: 10.3390/ijms18040870] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
221 Aptekorz M, Szczegielniak A, Wiechuła B, Harmanus C, Kuijper E, Martirosian G. Occurrence of Clostridium difficile ribotype 027 in hospitals of Silesia, Poland. Anaerobe 2017;45:106-13. [PMID: 28216085 DOI: 10.1016/j.anaerobe.2017.02.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
222 Sadeghi O, Milajerdi A, Siadat SD, Keshavarz SA, Sima AR, Vahedi H, Adibi P, Esmaillzadeh A. Effects of soy milk consumption on gut microbiota, inflammatory markers, and disease severity in patients with ulcerative colitis: a study protocol for a randomized clinical trial. Trials 2020;21:565. [PMID: 32576228 DOI: 10.1186/s13063-020-04523-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
223 Gandhi S, Jedel S, Hood MM, Mutlu E, Swanson G, Keshavarzian A. The relationship between coping, health competence and patient participation among patients with inactive inflammatory bowel disease. J Crohns Colitis 2014;8:401-8. [PMID: 24230968 DOI: 10.1016/j.crohns.2013.10.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
224 Scarpa M, Grillo A, Faggian D, Ruffolo C, Bonello E, D’Incà R, Scarpa M, Castagliuolo I, Angriman I. Relationship between mucosa-associated microbiota and inflammatory parameters in the ileal pouch after restorative proctocolectomy for ulcerative colitis. Surgery. 2011;150:56-67. [PMID: 21549404 DOI: 10.1016/j.surg.2011.02.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
225 Petri WA Jr, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric infections, diarrhea, and their impact on function and development. J Clin Invest 2008;118:1277-90. [PMID: 18382740 DOI: 10.1172/JCI34005] [Cited by in Crossref: 254] [Cited by in F6Publishing: 132] [Article Influence: 19.5] [Reference Citation Analysis]
226 Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524-534. [PMID: 16775498 DOI: 10.1097/00054725-200606000-00013] [Cited by in Crossref: 256] [Cited by in F6Publishing: 241] [Article Influence: 17.1] [Reference Citation Analysis]